Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
All Of Company’s Trials Halted
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
You may also be interested in...
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.